Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Succinylcholine Use and Dantrolene Availability for Malignant Hyperthermia Treatment: Database Analyses and Systematic Review.

Larach MG, Klumpner TT, Brandom BW, Vaughn MT, Belani KG, Herlich A, Kim TW, Limoncelli J, Riazi S, Sivak EL, Capacchione J, Mashman D, Kheterpal S, Kooij F, Wilczak J, Soto R, Berris J, Price Z, Lins S, Coles P, Harris JM, Cummings KC 3rd, Berman MF, Nanamori M, Adelman BT, Wedeven C, LaGorio J, McCormick PJ, Tom S, Aziz MF, Coffman T, Ellis TA 2nd, Molina S, Peterson W, Mackey SC, van Klei WA, Ginde AA, Biggs DA, Neuman MD, Craft RM, Pace NL, Paganelli WC, Durieux ME, Nair BJ, Wanderer JP, Miller SA, Helsten DL, Turnbull ZA, Schonberger RB; Multicenter Perioperative Outcomes Group.

Anesthesiology. 2019 Jan;130(1):41-54. doi: 10.1097/ALN.0000000000002490.

PMID:
30550426
2.

An Interprofessional Curriculum on Antimicrobial Stewardship Improves Knowledge and Attitudes Toward Appropriate Antimicrobial Use and Collaboration.

MacDougall C, Schwartz BS, Kim L, Nanamori M, Shekarchian S, Chin-Hong PV.

Open Forum Infect Dis. 2017 Jan 31;4(1):ofw225. doi: 10.1093/ofid/ofw225. eCollection 2017 Winter.

3.

Changes in saccharide, amino acid and S-methylmethionine content during malting of barley grown with different nitrogen and sulfur status.

Nanamori M, Watanabe T, Shinano T, Kihara M, Kawahara K, Yamada S, Osaki M.

J Sci Food Agric. 2011 Jan 15;91(1):85-93. doi: 10.1002/jsfa.4154. Epub 2010 Sep 2.

PMID:
20812384
4.
5.

Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1.

Zhou C, Zhang S, Nanamori M, Zhang Y, Liu Q, Li N, Sun M, Tian J, Ye PP, Cheng N, Ye RD, Wang MW.

Mol Pharmacol. 2007 Oct;72(4):976-83. Epub 2007 Jul 25. Erratum in: Mol Pharmacol. 2007 Nov;72(5):1391.

PMID:
17652444
7.

The immunosuppressant cyclosporin A antagonizes human formyl peptide receptor through inhibition of cognate ligand binding.

Yan P, Nanamori M, Sun M, Zhou C, Cheng N, Li N, Zheng W, Xiao L, Xie X, Ye RD, Wang MW.

J Immunol. 2006 Nov 15;177(10):7050-8.

8.
9.

RGS-insensitive G-protein mutations to study the role of endogenous RGS proteins.

Fu Y, Zhong H, Nanamori M, Mortensen RM, Huang X, Lan K, Neubig RR.

Methods Enzymol. 2004;389:229-43. Review.

PMID:
15313569
10.

A novel nonpeptide ligand for formyl peptide receptor-like 1.

Nanamori M, Cheng X, Mei J, Sang H, Xuan Y, Zhou C, Wang MW, Ye RD.

Mol Pharmacol. 2004 Nov;66(5):1213-22. Epub 2004 Aug 12.

PMID:
15308762
12.
13.

AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs.

Seta K, Nanamori M, Modrall JG, Neubig RR, Sadoshima J.

J Biol Chem. 2002 Mar 15;277(11):9268-77. Epub 2002 Jan 3.

14.

ANG II type 1 receptor downregulation does not require receptor endocytosis or G protein coupling.

Modrall JG, Nanamori M, Sadoshima J, Barnhart DC, Stanley JC, Neubig RR.

Am J Physiol Cell Physiol. 2001 Sep;281(3):C801-9.

15.

Molecular cloning and characterization of a novel regulator of G-protein signaling from mouse hematopoietic stem cells.

Park IK, Klug CA, Li K, Jerabek L, Li L, Nanamori M, Neubig RR, Hood L, Weissman IL, Clarke MF.

J Biol Chem. 2001 Jan 12;276(2):915-23.

16.
17.

G(i) activator region of alpha(2A)-adrenergic receptors: distinct basic residues mediate G(i) versus G(s) activation.

Wade SM, Lim WK, Lan KL, Chung DA, Nanamori M, Neubig RR.

Mol Pharmacol. 1999 Nov;56(5):1005-13.

PMID:
10531407

Supplemental Content

Loading ...
Support Center